Systemic light chain and transthyretin amyloidosis-treatment advancements and future directions
Listen to this summary
This review addresses the recent advancements in the treatment of systemic light chain (AL) and transthyretin (ATTR) amyloidosis, aiming to highlight the molecular mechanisms driving these diseases and the implications for therapy. The authors discuss the emergence of effective treatments, including six novel therapies for ATTR and a combination therapy for AL, while emphasizing the importance of early diagnosis and intervention. Future directions and challenges in achieving a cure for these conditions are also explored.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Lancet (London, England)
View all →Jul 10, 2026 · Lancet (London, England)
Advancing the relevance of clinical trials for older patients
Jul 9, 2026 · Lancet (London, England)
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial
Jul 9, 2026 · Lancet (London, England)
Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial
Jul 9, 2026 · Lancet (London, England)
Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations
Jul 7, 2026 · Lancet (London, England)
Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial
Jul 6, 2026 · Lancet (London, England)
Inherited retinal degenerations: clinical phenotypes and emerging therapies
More in Nuclear Medicine
View all →Jul 8, 2026 · The New England journal of medicine
Ensartinib in Resected <em>ALK</em>-Positive Non-Small-Cell Lung Cancer
Jul 8, 2026 · The New England journal of medicine
Meningococcal B Vaccine to Prevent <em>Neisseria gonorrhoeae</em> Infection
Jul 8, 2026 · The New England journal of medicine
Nutrition Therapy in Critically Ill Adults
Jul 8, 2026 · The New England journal of medicine
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity
Jul 3, 2026 · Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Clinical Application and Research Advances of PET Molecular Imaging in Immune Checkpoint Inhibitor-Associated Myocarditis
Jul 2, 2026 · Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Immuno-PET in Cardiovascular Disease: Advances, Challenges, and Opportunities
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
